$0.93 EPS Expected for IDEXX Laboratories, Inc. (IDXX) on May, 4

May 3, 2018 - By Gregory Tomko

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Corporate Logo
Big Money Sentiment decreased to 0.81 in 2017 Q4. It has change of 0.05, from 2017Q3’s 0.86. The ratio fall due to IDEXX Laboratories, Inc. positioning: 30 sold and 217 reduced. 64 funds bought holdings and 137 increased holdings. Investors holded 87.85 million in 2017Q3 but now own 72.13 million shares or 17.89% less.
Zurcher Kantonalbank (Zurich Cantonalbank) reported 0.03% of its capital in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Moreover, Credit Suisse Ag has 0.07% invested in IDEXX Laboratories, Inc. (NASDAQ:IDXX). 966 were reported by Commonwealth Savings Bank Of. Bancshares Of Ny Mellon reported 1.14 million shs. Metropolitan Life Ny, a New York-based fund reported 17,263 shs. Catalyst Ltd Co holds 0.1% of its capital in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 17,600 shs. Daiwa Secs Group holds 0% of its capital in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 2,599 shs. Moreover, Ahl Prtnrs Llp has 0.06% invested in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Vanguard Gru, a Pennsylvania-based fund reported 9.10M shs. Evercore Wealth Mngmt Lc holds 0.35% or 59,974 shs in its capital. Northern holds 1.02 million shs. Sandhill Cap Ptnrs Ltd reported 89,518 shs stake. Aviva Public Ltd Liability holds 0.04% or 48,976 shs. Eads & Heald Inv Counsel has invested 0.69% of its capital in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Profund Limited Liability Co has invested 0.05% in IDEXX Laboratories, Inc. (NASDAQ:IDXX).

IDEXX Laboratories, Inc. registered $21.47 million net activity with 2 insider buys and 6 insider sales since January 9, 2018. The insider MCKEON BRIAN P sold 6,602 shs worth $1.20M. On Wednesday, February 28 JUNIUS DANIEL M sold $565,232 worth of IDEXX Laboratories, Inc. (NASDAQ:IDXX). $178,045 worth of stock was bought by Kingsley Lawrence D on Wednesday, February 14. On Wednesday, February 7 the insider AYERS JONATHAN W sold $3.91M. $737,939 worth of stock was sold by END WILLIAM T on Thursday, February 22.

Earnings report for IDEXX Laboratories, Inc. (NASDAQ:IDXX) is anticipated on May, 4 before the open., as reported by Faxor. Analysts have expectation on stock’s earnings per share of $0.93. That’s up 43.08 % from last year’s $0.65 earnings per share. The profit will be $80.97 million for IDXX if $0.93 earnings per share becomes true. Wall Street sees 20.78 % EPS growth as of May, 4. Ticker’s shares touched $193.17 during the last trading session after 0.97% change.Currently IDEXX Laboratories, Inc. is uptrending after 23.99% change in last May 3, 2017. IDXX has also 509,027 shares volume. IDXX outperformed the S&P500 by 12.44%.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Ratings Coverage

In total 5 analysts cover IDEXX Laboratories (NASDAQ:IDXX). “Buy” rating has 5, “Sell” are 0, while 0 are “Hold”. (NASDAQ:IDXX) has 100% bullish analysts. 5 are the (NASDAQ:IDXX)’s ratings reports on May 3, 2018 according to StockzIntelligence Inc. On Thursday, February 1 the firm earned “Buy” rating by Stifel Nicolaus. On Monday, January 29 Canaccord Genuity maintained IDEXX Laboratories, Inc. (NASDAQ:IDXX) with “Buy” rating. On Friday, February 2 Bank of America maintained the shares of IDXX in report with “Buy” rating.

IDEXX Laboratories, Inc., together with its subsidiaries, develops, makes, and distributes services and products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide.The firm is valued at $16.82 billion. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other divisions.The P/E ratio is 65.7. The firm provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assays; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.